CNSide — Regulatory decision
Nov 2026
Medicare rate expected effective Jan 1, 2027; CMS final pricing expected November 2026Source filing
CNSY biotech catalysts & pipeline
CERENOME INC · Data as of 2026-10-27
Upcoming catalysts
rhenium (186Re) obisbemeda (REYOBIQ) — Interim data
Nov 12–Nov 15
Cerenome, Inc. Company to provide latest clinical trial data and highlight evolving approaches to leptomeningeal metastases diagnosis and treatment in a company sponsored symposium 2026 SNO Annual Meeting to be held on November 12-15 in Philadelphia HOUSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence today announced that a poster presentation of interim data from its ongoing ReSPECT-LMM multidose study of REYOBIQ™ (rhenium Re186 obisbemeda) will be presented at the Society for Neuro-Oncology ("SNO") 31 st Annual Meeting and Education Day , taking place November 12–15, 2026, at the Pennsylvania Convention Center in Philadelphia.Source filing
CNSide — Regulatory decision
Jan 1
Medicare rate expected effective Jan 1, 2027; CMS final pricing expected November 2026Source filing
GBM — Clinical data readout
1H 2027
GBM phase 2 read out 1H 2027Source filing
rhenium (186Re) obisbemeda (REYOBIQ) — Clinical data readout
Q1 2027
Complete enrollment in the ReSPECT-GBM Phase 2 trial for glioblastoma; data is expected in Q1 2027, followed by an End-of-Phase 2 meeting with the FDASource filing
rhenium (186Re) obisbemeda (REYOBIQ) — Conference presentation
Nov 13
Date and Time: Friday, November 13, 2026, 7:30–9:30 p.m. ETSource filing